Vanguard Fiduciary Trust
AMLX icon

Vanguard Fiduciary Trust’s Amylyx Pharmaceuticals AMLX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
623,078
+36,926
+6% +$571K ﹤0.01% 1753
2026
Q1 		$8.15M Buy
+586,152
New +$8.24M ﹤0.01% 1827

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Fiduciary Trust's AMLX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Amylyx Pharmaceuticals (AMLX) stake by 6.3% in Q2 2026, buying an estimated $571K and bringing the position to 623,078 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Vanguard Fiduciary Trust first reported a position in AMLX in Q1 2026 and has held it in 2 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Vanguard Fiduciary Trust held 623,078 shares of Amylyx Pharmaceuticals worth $11.2M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 36,926 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1753 holding.
  • Vanguard Fiduciary Trust first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.